Wuxi Biologics Unspadr2 Stock Total Debt
| 1FW1 Stock | EUR 7.00 0.30 4.11% |
Fundamental analysis of WUXI BIOLOGICS allows traders to better anticipate movements in WUXI BIOLOGICS's stock price by examining its financial health and performance throughout various phases of its business cycle.
WUXI |
WUXI BIOLOGICS UNSPADR2 Company Total Debt Analysis
WUXI BIOLOGICS's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current WUXI BIOLOGICS Total Debt | 3.33 B |
Most of WUXI BIOLOGICS's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WUXI BIOLOGICS UNSPADR2 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, WUXI BIOLOGICS UNSPADR2 has a Total Debt of 3.33 B. This is 21.04% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The total debt for all Germany stocks is 37.37% higher than that of the company.
WUXI Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WUXI BIOLOGICS's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of WUXI BIOLOGICS could also be used in its relative valuation, which is a method of valuing WUXI BIOLOGICS by comparing valuation metrics of similar companies.WUXI BIOLOGICS is currently under evaluation in total debt category among its peers.
WUXI Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 238.12 X | |||
| Revenue | 13.09 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.6 B | |||
| Net Income | 1.69 B | |||
| Cash And Equivalents | 8.48 B | |||
| Cash Per Share | 4.15 X | |||
| Total Debt | 3.33 B | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 3.16 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 1.88 B | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 32.39 B | |||
| Z Score | 5.4 |
About WUXI BIOLOGICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WUXI BIOLOGICS UNSPADR2's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WUXI BIOLOGICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WUXI BIOLOGICS UNSPADR2 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in WUXI Stock
WUXI BIOLOGICS financial ratios help investors to determine whether WUXI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WUXI with respect to the benefits of owning WUXI BIOLOGICS security.